These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7661308)

  • 1. The ototoxicity of deferoxamine mesylate.
    Kanno H; Yamanobe S; Rybak LP
    Am J Otolaryngol; 1995; 16(3):148-52. PubMed ID: 7661308
    [No Abstract]   [Full Text] [Related]  

  • 2. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M; Arigliani R; Molinari AC; Tarantino V
    Pediatr Med Chir; 1986; 8(5):703-5. PubMed ID: 3601700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can deferoxamine be considered an ototoxic drug?
    Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
    Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ototoxicity of deferoxamine].
    de España R; Biurrun O; Lorente J; Valls J; Orteu N; Traserra J
    An Otorrinolaringol Ibero Am; 1992; 19(4):341-7. PubMed ID: 1636908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U; Dondè E; Piatti G; Cappellini MD
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hearing loss after taking a header into water].
    Stuermer KJ; Luers JC; Beutner D
    Laryngorhinootologie; 2011 Jun; 90(6):369-70. PubMed ID: 20799155
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
    Triantafyllou N; Fisfis M; Sideris G; Triantafyllou D; Rombos A; Vrettou H; Mantouvalos V; Politi C; Malliara S; Papageorgiou C
    Acta Neurol Scand; 1991 May; 83(5):306-8. PubMed ID: 1648295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M; Meleleo D; Tricarico N; Greco Miani A; Serra E; Parlatore L
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hearing loss in the 4-8 kHz range following tympanic membrane perforation from minor trauma.
    Hussain SS
    Clin Otolaryngol Allied Sci; 1995 Jun; 20(3):211-2. PubMed ID: 7554328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulsatile tinnitus cured by mastoidectomy.
    Duvillard C; Ballester M; Redon E; Romanet P
    Ann Otol Rhinol Laryngol; 2004 Sep; 113(9):730-3. PubMed ID: 15453531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of conductive hearing loss due to posterior semicircular canal dehiscence.
    Kubota M; Kubo K; Yasui T; Matsumoto N; Komune S
    Auris Nasus Larynx; 2015 Jun; 42(3):245-8. PubMed ID: 25466358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paget's disease and hearing loss.
    Harner SG; Rose DE; Facer GW
    Otolaryngology; 1978; 86(6 Pt 1):ORL-869-74. PubMed ID: 113745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conductive hearing loss: investigation of possible inner ear origin in three cases studies.
    Al Muhaimeed H; El Sayed Y; Rabah A; Al-Essa A
    J Laryngol Otol; 2002 Nov; 116(11):942-5. PubMed ID: 12487675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hearing impairment during deferoxamine therapy for thalassemia major.
    Argiolu F; Diana G; Avignone A; Cao A; Di Ninni S
    J Pediatr; 1991 May; 118(5):826-7. PubMed ID: 2019945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.